New York, Feb 4, 2026, 05:14 (EST) — Premarket
Eli Lilly (LLY.N) shares dipped slightly in premarket trading Wednesday, following a steep decline the day before that thrust the drugmaker back into focus in the obesity-drug sector. The stock was down roughly 0.5% at $998.50, after closing Tuesday at $1,003.21, slipping nearly 4%.
Sentiment has turned negative across the sector after Novo Nordisk issued a warning that 2026 sales and profits could drop by up to 13%, blaming “unprecedented pricing pressure” in the U.S. alongside policy efforts to lower drug costs. Novo has responded by cutting prices and rolling out an oral version of Wegovy in the U.S. At the same time, Lilly announced it plans to cap higher doses of its obesity drug — if approved — at $399 per month for repeat cash buyers. Reuters
The outlook for the market that fueled Lilly’s growth has taken a sharp turn. “That $150 billion pie is gone,” Jefferies analyst Michael Leuchten noted, with some investors now eyeing a smaller $80 billion to $105 billion market by 2030. Attention is shifting toward the cash-pay segment, where patients cover costs directly rather than through insurance. Reuters
Tuesday’s drop came after Novo’s disappointing 2026 forecast and dragged down U.S.-listed peers. Citizens equity research analyst Jonathan Wolleben noted, “Novo’s showing there’s a market for oral options,” highlighting steady demand if injections hit snags. Pfizer’s shares also dipped after trial results for its monthly GLP-1 injection failed to impress investors. Reuters
GLP-1 is trader shorthand for a drug class that mimics a natural gut hormone, helping to lower blood sugar after meals. According to the U.S. Food and Drug Administration, these drugs also target brain areas that regulate appetite and food intake. That’s why they’re now a key player in the obesity market.
For Lilly, the key issue is if volume growth and supply improvements can make up for ongoing price cuts, particularly in the cash-pay market. Traders will also focus on how the company discusses competition from pills and follow-on products, along with its outlook for insurers and pharmacy benefit managers.
A regulatory filing revealed a more subtle update on insider holdings. CEO David Ricks was issued 31,932 shares as restricted stock units vested and sold 14,296.654 shares at $1,037.15 in a linked transaction; restricted stock units are equity awards that turn into shares upon vesting.
But the situation works both ways. If Lilly’s forecast suggests pricing pressure is ramping up quicker than anticipated, or if wider policy shifts are beginning to have an impact, the stock might suffer another drop despite strong demand.
Lilly plans to release its fourth-quarter 2025 results on Wednesday, followed by a conference call at 10 a.m. Eastern. Investors will closely watch this as a key indicator of the company’s pricing power in the obesity-drug sector.
